Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kai Kessenbrock, Leopold Fröhlich, Michael Sixt, Tim Lämmermann, Heiko Pfister, Andrew Bateman, Azzaq Belaaouaj, Johannes Ring, Markus Ollert, Reinhard Fässler, Dieter E. Jenne
Published in Volume 118, Issue 7
J Clin Invest. 2008; 118(7):2438–2447 doi:10.1172/JCI34694
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 6
PGRN is a potent inhibitor of IC-stimulated inflammation in vivo.

Recombinant mouse PGRN (2 μg) was intradermally applied with anti-OVA IgG, and the RPA was started in WT and Prtn3–/–Ela2–/– mice (n = 5 per group). (A) After 4 h, the effect of PGRN application was evaluated by histological analyses. Representative images show neutrophil infiltrates at the panniculus carnosus muscle (asterisks). Scale bars: 200 μm. (B and C) Effect of PGRN administration on neutrophil influx. In both WT (B) and Prtn3–/–Ela2–/– (C) mice, neutrophil infiltration was significantly diminished at PGRN-treated sites compared with untreated sites. This effect appeared to be more pronounced in the protease-deficient mice. Data are mean ± SEM infiltrated neutrophils per HPF. *P < 0.05; **P < 0.01. (D) Neutrophils isolated ex vivo from inflamed peritoneum of WT and Prtn3–/–Ela2–/– mice were analyzed by anti-mouse PGRN Western blot of concentrated neutrophil lysates. Intact PGRN was found abundantly in Prtn3–/–Ela2–/– but not WT neutrophils. Loading was controlled using anti-actin Western blot.